TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model

TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model

BackgroundEwing sarcoma (EwS) is an aggressive and highly metastatic bone and soft tissue tumor in pediatric patients and young adults. Cure rates are low when patients present with metastatic or relapsed disease. Therefore, innovative therapy approaches are urgently needed. Cellular- and oncolytic...

Full description

Bibliographic Details
Main Authors: Sebastian J. Schober, Melanie Thiede, Hendrik Gassmann, Anna Josefine von Ofen, Pia Knoch, Jennifer Eck, Carolin Prexler, Corazon Kordass-Wally, Julia Hauer, Stefan Burdach, Per Sonne Holm, Uwe Thiel
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Immunology
Subjects:
pediatric sarcoma
Ewing sarcoma
oncolytic virotherapy
TCR-transgenic T cells
combination immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1330868/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1330868/full

Similar Items